Johanna Mercier's Insider Trades & SAST Disclosures
Johanna Mercier's most recent trade in Gilead Sciences, Inc. was a trade of 49,020 Non-qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Johanna Mercier.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 49,020 | 49,020 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 11,090 | 39,203 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 8,080 | 28,113 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 8,080 | 128,059 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.21 per share. | 10 Mar 2025 | 3,907 | 124,152 (0%) | 0% | 117.2 | 457,939 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 70,712 | 165,645 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 97.99 per share. | 04 Feb 2025 | 45,666 | 119,979 (0%) | 0% | 98.0 | 4,474,811 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 19,793 | 94,933 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 3,752 | 36,193 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 3,752 | 76,879 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.34 per share. | 10 Dec 2024 | 1,739 | 75,140 (0%) | 0% | 92.3 | 160,579 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 91.28 per share. | 06 Nov 2024 | 5,000 | 73,127 (0%) | 0% | 91.3 | 456,400 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 84.23 per share. | 12 Sep 2024 | 15,925 | 91,559 (0%) | 0% | 84.2 | 1,341,363 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 83.25 per share. | 12 Sep 2024 | 13,432 | 78,127 (0%) | 0% | 83.3 | 1,118,214 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 3,752 | 39,945 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 3,752 | 109,218 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.44 per share. | 10 Sep 2024 | 1,734 | 107,484 (0%) | 0% | 81.4 | 141,217 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 78.03 per share. | 28 Aug 2024 | 9,513 | 105,466 (0%) | 0% | 78.0 | 742,299 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 73.98 per share. | 13 Aug 2024 | 5,490 | 114,979 (0%) | 0% | 74.0 | 406,150 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 3,751 | 122,183 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 3,751 | 43,697 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.25 per share. | 10 Jun 2024 | 1,714 | 120,469 (0%) | 0% | 65.3 | 111,839 | Common Stock |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 2,982 | 2,982 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,435 | 1,435 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 2,100 | 2,100 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 87,970 | 87,970 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 17,305 | 47,448 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,819 | 30,143 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 6,819 | 122,991 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.12 per share. | 10 Mar 2024 | 4,559 | 118,432 (0%) | 0% | 75.1 | 342,472 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 3,025 | 116,172 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 3,025 | 36,962 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 53,969 | 135,656 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.26 per share. | 31 Jan 2024 | 22,509 | 113,147 (0%) | 0% | 78.3 | 1,761,554 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 20,086 | 81,687 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 85.23 per share. | 09 Jan 2024 | 8,242 | 82,729 (0%) | 0% | 85.2 | 702,466 | Common Stock |
| Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 2,730 | 39,987 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2023 | 2,730 | 92,218 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.02 per share. | 10 Dec 2023 | 1,247 | 90,971 (0%) | 0% | 79.0 | 98,538 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2023 | 2,730 | 42,717 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2023 | 2,730 | 90,744 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.00 per share. | 10 Sep 2023 | 1,256 | 89,488 (0%) | 0% | 76 | 95,456 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2023 | 7,505 | 45,447 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2023 | 7,505 | 51,500 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.66 per share. | 24 Jul 2023 | 3,174 | 48,326 (0%) | 0% | 77.7 | 246,493 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 2,730 | 45,267 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 2,730 | 52,952 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.12 per share. | 10 Jun 2023 | 1,272 | 43,995 (0%) | 0% | 78.1 | 99,369 | Common Stock |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 4,290 | 4,290 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 2,100 | 2,100 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 74,565 | 74,565 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 16,350 | 55,682 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,951 | 87,341 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 7,951 | 39,332 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.50 per share. | 10 Mar 2023 | 5,116 | 82,225 (0%) | 0% | 79.5 | 406,722 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 3,025 | 79,390 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 3,025 | 47,283 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 38,270 | 91,690 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2023 | 29,124 | 53,420 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.02 per share. | 24 Jan 2023 | 15,325 | 76,365 (0%) | 0% | 84.0 | 1,287,607 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2022 | 990 | 50,308 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2022 | 990 | 40,893 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.97 per share. | 10 Dec 2022 | 463 | 40,430 (0%) | 0% | 88.0 | 40,730 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2022 | 990 | 40,361 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2022 | 990 | 51,298 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.28 per share. | 10 Sep 2022 | 458 | 39,903 (0%) | 0% | 65.3 | 29,898 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2022 | 7,505 | 52,288 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2022 | 7,505 | 42,577 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.80 per share. | 24 Jul 2022 | 3,206 | 39,371 (0%) | 0% | 60.8 | 194,925 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 990 | 35,534 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 990 | 59,793 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.74 per share. | 10 Jun 2022 | 462 | 35,072 (0%) | 0% | 60.7 | 28,062 | Common Stock |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 9,724 | 9,724 | - | - | Non-Qualified Stock Option | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 171,670 | 171,670 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 27,840 | 60,783 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 3,962 | 32,943 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 3,962 | 37,765 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.92 per share. | 10 Mar 2022 | 3,221 | 34,544 (0%) | 0% | 57.9 | 186,560 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 3,025 | 36,905 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 3,025 | 33,803 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2021 | 7,505 | 15,573 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2021 | 7,505 | 39,930 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.02 per share. | 24 Jul 2021 | 3,425 | 12,148 (0%) | 0% | 69.0 | 236,394 | Common Stock |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 8,833 | 8,833 | - | - | Non-Qualified Stock Option | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 66.09 per share. | 04 May 2021 | 19,496 | 8,068 (0%) | 0% | 66.1 | 1,288,547 | Common Stock |
| Neurocrine Biosciences, Inc. | Johanna Mercier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 17,180 | 17,180 | - | - | Non-Qualified Stock Option | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 92,205 | 92,205 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 15,845 | 47,435 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 3,025 | 31,590 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 3,025 | 28,999 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.91 per share. | 10 Mar 2021 | 1,435 | 27,564 (0%) | 0% | 63.9 | 91,711 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 8,068 | 25,974 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2020 | 26,270 | 30,188 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.83 per share. | 03 Nov 2020 | 12,282 | 17,906 (0%) | 0% | 58.8 | 722,550 | Common Stock |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2020 | 7,505 | 7,505 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2020 | 7,505 | 34,615 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Johanna Mercier | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.64 per share. | 24 Jul 2020 | 3,587 | 3,918 (0%) | 0% | 73.6 | 264,147 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges